Dr. Reddy's Laboratories Limited (NYSE:RDY) Shares Acquired by Ethic Inc.

Ethic Inc. lifted its holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 422.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 23,073 shares of the company's stock after acquiring an additional 18,655 shares during the quarter. Ethic Inc.'s holdings in Dr. Reddy's Laboratories were worth $364,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the business. EverSource Wealth Advisors LLC increased its stake in shares of Dr. Reddy's Laboratories by 423.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company's stock worth $29,000 after buying an additional 1,507 shares during the period. Glass Jacobson Investment Advisors llc boosted its holdings in Dr. Reddy's Laboratories by 400.0% in the fourth quarter. Glass Jacobson Investment Advisors llc now owns 2,000 shares of the company's stock valued at $32,000 after acquiring an additional 1,600 shares in the last quarter. POM Investment Strategies LLC lifted its position in shares of Dr. Reddy's Laboratories by 400.0% in the 4th quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock worth $36,000 after purchasing an additional 1,820 shares during the period. Farther Finance Advisors LLC increased its position in shares of Dr. Reddy's Laboratories by 461.0% during the fourth quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company's stock valued at $40,000 after buying an additional 2,093 shares during the period. Finally, Allworth Financial LP boosted its position in Dr. Reddy's Laboratories by 447.8% during the 4th quarter. Allworth Financial LP now owns 2,728 shares of the company's stock valued at $41,000 after acquiring an additional 2,230 shares in the last quarter. Hedge funds and other institutional investors own 3.85% of the company's stock.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a report on Thursday, May 8th.

Dr. Reddy's Laboratories Price Performance

Shares of NYSE:RDY traded up $0.02 during midday trading on Tuesday, reaching $14.48. 1,629,432 shares of the company were exchanged, compared to its average volume of 1,491,049. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. The stock has a market cap of $12.09 billion, a PE ratio of 23.06 and a beta of 0.33. Dr. Reddy's Laboratories Limited has a one year low of $12.26 and a one year high of $16.89. The business's fifty day moving average is $13.47 and its two-hundred day moving average is $14.03.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its quarterly earnings results on Friday, May 9th. The company reported $0.22 EPS for the quarter, beating the consensus estimate of $0.20 by $0.02. The business had revenue of $996.17 million during the quarter, compared to analyst estimates of $83.70 billion. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. As a group, analysts predict that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current year.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.